Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism

被引:143
作者
Baillie, Thomas A. [1 ]
机构
[1] Merck Res Labs, Dept Drug Metab & Pharmacokinet, West Point, PA 19486 USA
关键词
D O I
10.1021/tx7002273
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The science of drug metabolism and pharmacokinetics (DMPK) has developed significantly over the past 20 years, and its functional role in today's pharmaceutical industry has matured to the point where DMPK has become an indispensable discipline in support of drug discovery and development. While contributions to the lead optimization phase of discovery efforts have been particularly noteworthy in helping to select only the best drug candidates for entry into development, it should be recognized that the scope of DMPK spans the continuum of discovery through clinical evaluation and even into the post-marketing phase; as such, the breadth of DMPK's involvement is almost unique in contemporary pharmaceutical research. This perspective summarizes notable advances in the field, many of which have been made possible by technological developments in areas such as molecular biology, genetics, and bioanalytical chemistry, and highlights the critical nature of key partnerships between Drug Metabolism, Medicinal Chemistry, and Safety Assessment groups in attempting to advance drug candidates with a low potential for causing adverse events in humans. Finally, some speculative predictions are made of the future role of DMPK in pharmaceutical research, where current advances in our mechanistic understanding of the molecular processes that control the absorption, disposition, metabolism, elimination, and toxicity of drugs and their biotransformation products will combine to further enhance the impact of DMPK in drug discovery and development.
引用
收藏
页码:129 / 137
页数:9
相关论文
共 79 条
  • [11] Ambient mass spectrometry
    Cooks, RG
    Ouyang, Z
    Takats, Z
    Wiseman, JM
    [J]. SCIENCE, 2006, 311 (5767) : 1566 - 1570
  • [12] A regulatory perspective on issues and approaches in characterizing human metabolites
    Davis-Bruno, Karen L.
    Atrakchi, Aisar
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (12) : 1561 - 1563
  • [13] Day S. H., 2005, Journal of Pharmacological and Toxicological Methods, V52, P278, DOI 10.1016/j.vascn.2004.11.006
  • [14] Interfering with disease: a progress report on siRNA-based therapeutics
    de Fougerolles, Antonin
    Vornlocher, Hans-Peter
    Maraganore, John
    Lieberman, Judy
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (06) : 443 - 453
  • [15] Cytosolic and nuclear protein targets of thiol-reactive electrophiles
    Dennehy, MK
    Richards, KAM
    Wernke, GR
    Shyr, Y
    Liebler, DC
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (01) : 20 - 29
  • [16] Review - Mass spectrometry and protein analysis
    Domon, B
    Aebersold, R
    [J]. SCIENCE, 2006, 312 (5771) : 212 - 217
  • [17] Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology
    Erve, John C. L.
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (06) : 923 - 946
  • [18] Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development
    Evans, DC
    Watt, AP
    Nicoll-Griffith, DA
    Baillie, TA
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2004, 17 (01) : 3 - 16
  • [19] Pharmacogenetics of thiopurine S-Methyltransferase and thiopurine therapy
    Evans, WE
    [J]. THERAPEUTIC DRUG MONITORING, 2004, 26 (02) : 186 - 191
  • [20] High-throughput in vitro profiling assays:: lessons learnt from experiences at Novartis
    Faller, Bernard
    Wang, Jianling
    Zimmerlin, Alfred
    Bell, Leslie
    Hamon, Jacques
    Whitebread, Steven
    Azzaoui, Kamal
    Bojanic, Dejan
    Urban, Laszlo
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2006, 2 (06) : 823 - 833